mix bag profit disappoint order momentum
remain strong reduc price
top line varian deliv revenu million versu estim
million consensu estim million oncolog system
revenu million versu estim million well tri
better next time proton solut segment deliv million
revenu versu estim million gross oncolog order
quarter increas whop report constant currenc
proton solut busi continu struggl term order
busi select prefer provid key cancer hospit
china hope order end quarter
bottom line varian report non-gaap ep figur quarter
versu expect consensu estim lower-than-
expect gross margin result weigh tariff headwind difficulti
within proton busi primari reason non-gaap ep miss
balanc sheet cash flow varian end quarter cash
equival approxim million debt flow
oper quarter million million versu
outlook varian affirm financi guidanc rais top-lin
outlook guidanc includ assumpt revenu growth
revenu growth previous non-gaap ep rang
cash flow oper rang million non-
effect tax rate expect
weight averag share count around million reduc
non-gaap ep estim previous
recommend maintain outperform invest rate
share slightli lower price target arriv
price target attach multipl adjust ebitda estim
assum million net cash month
revenu mil estimate bold
ep estimate bold
upsid price
return equiti ltm
note pleas refer page end
report import disclosur
overal fiscal second quarter result continu demonstr varian strong order
momentum compani believ allow captur meaning market
share past year said varian also fell well short analyst profit
estim due rel weak gross margin perform larg driven
compani continu struggl within proton busi increas project cost
associ one custom site delay appear neg impact
busi expect issu persist beyond impact
lastli varian affirm previously-provid non-gaap ep guidanc
slightli increas guidanc revenu growth year
previou growth expect
revenu look revenu oper segment oncolog system revenu came
million basic line million estim revenu
segment increas around versu compar period last year product
revenu growth quarter servic increas approxim
varian proton solut segment deliv million revenu increas
around versu compar quarter last year estim busi
gross margin oper expens total consolid gross margin came
versu estim non-gaap gross margin
decreas bp versu last year compar quarter tariff headwind proton
difficulti foreign currenc headwind primari driver unfavor
yoy proton busi lost million gross margin line quarter
repres neg comparison bp
sg expens came expect non- sg
expens expens revenu versu model
profit non-gaap ep came fell well short estim
well consensu expect
balanc sheet cash flow varian end quarter cash equival
approxim million debt flow oper neg
million quarter around million
varian report bit mix bag quarter order growth remain except
strong report constant currenc non-gaap profit
fall meaning short expect manag affirm previously-
provid financi outlook rais revenu guidanc slightli
remind varian financi guidanc includ expect
overal revenu growth non-gaap ep non-gaap oper margin
oper cash flow million current model
non-gaap ep revenu growth previou non-gaap ep
expect cash flow expect also consist varian
guidanc albeit lower end rang
varian believ continu captur market share radiat therapi market
estim grow around compani busi momentum
past sever quarter best evidenc eye-pop oncolog order result
quit impress manag appear think current momentum could
easili sustain next sever quarter
manag larg blame profit miss continu issu within
proton busi appear one custom identifi experienc increas
unforeseen project cost quarter evid account million
drag associ busi delay also caus bit financi
headwind within segment cours tariff also continu neg impact
varian near-term result impact appear larg line
remind manag previous state compani mitig
gross tariff figur full year million origin
million estim impact variou lever includ suppli chain re-
phase certain project compani said remain track achiev
goal seem indic certainli benefit mitig effort
posit impact seen
sinc compani tariff mitig effort like impact incom
statement back half model easili
strongest quarter year compani term non-gaap ep cash
quarter oncolog system revenu increas dollar constant
currenc result larg driven revenu growth america region
constant currenc asia-pacif region also show solid revenu growth
increas report constant currenc emea region increas
report constant currenc
oncolog gross order grew report dollar constant
currenc repres strong result one appear
america order million increas report
constant currenc win includ scripp healthcar allianc oncolog
europ middl east india africa region gross oncolog order increas
dollar million constant currenc region
consecut double-digit growth perform includ meaning win great
britain germani demark saudi arabia well three-year deal tata trust
india prefer supplier
gross oncolog order asia-pacif region million increas
dollar constant currenc china japan indonesia cite
manag area meaning order captur
compani net instal base unit increas versu
period last year
compani gener addit halcyon order quarter bring
total sinc product first unveil vienna may order
halcyon quarter place compani report region
varian continu see strong demand softwar solut softwar
revenu increas quarter hardwar growth rate
varian also disclos softwar custom base grew quarter
excess custom overal
varian proton solut busi gener million revenu
quarter book new busi said compani prefer
provid shandong cancer hospit china expect receiv order
end current quarter
remind five quarter sinc new order book within
varian proton solut busi margin proton solut segment even ex
unusu headwind remain well compani averag
compani state longer expect achiev break-even profit
within proton segment said manag clearli remain hope
close addit proton order even beyond new busi expect
close shandong cancer hospit near term
varian continu excit understand potenti new
flash technolog earli pre-clin work appear hold promis amazingli quick
treatment throughput attack cancer tumor larg spare healthi
tissu trial could begin within month believ initi
could ultim success result genuin paradigm shift radiat therapi
varian continu activ share repurchas activ repurchas
approxim million share quarter share
compani still million share remain current share repurchas
compani updat guidanc includ million addit revenu
increas top-lin guidanc million benefit estim
reduct gross tariff impact compani also make increment invest
flash technolog research initi around million well million
increment invest softwar deploy capabl neither
increment invest anticip origin financi guidanc
look compani cash flow improv dramat
compani work recent intent inventori build also bring
high level focu collect somewhat elev receiv manag
confid recent spike dso materi revers next coupl
longer term optimist compani recent step-up order momentum
translat acceler revenu beyond
model accordingli believ also featur solid
margin expans perhap even excess model still envis
adjust oper margin
maintain outperform invest rate share slightli
reduc price target arriv price target attach
multipl adjust ebitda estim assum million
net cash month
revenu
interest incom net
 revenu
sg revenu
pre-shar repo chg wc
million except per share data
 xp ec ted ut pe th rke xt th
 xp ec ted rfo rm ro gh ly th ke ne nth
lo -ter te nti exi ts nea -te rm ca ta ly
 xp ec ted de er fo rm th rk et ov er xt th
co ny fu ta ls de te ri ra tin
fu va lu ov r- va lu cu le ls
 lo ri ce ta ge fo thi co pa se /e da th ho
ri ks th ta rg pri ce wi ch ie clu ut ot im ite fai lu
co ur ar ing stim te
th fo wi ng li ra tin fo co pa ie co rr ton ea ch cia te
inc ch th co es ra te ut rfo rm wa nd
 se te al co ni es th ov ra ist th um co pa ie ate
 rf rm es ent co ni es th co age ist
th um co ani ra te un rp fo wa se te al
th co ra ist lso rch rin se rch
sso cia te rovid ed tm en nk se vice th mo th
 th co ni th tp fo ra tin om ie
tha fo ti nd th co mp ie th ha
na ly er tific ion se rc ana yst spo ns ib le fo th ra tio th es ea ch por ich tu sk fa eb ce rti fi
 vi ws ut th om nd th ei se cu iti xp ss th rt accu ate fle ct hi er op ni ns lyst lso
ce rti fi th rt hi co pe sa ti di ctl dir ctli el te th pe ci fic comm ati vie co ta th rt
 es ea ch na lyst cl di th os invo lv ed th ep ati thi rt ce ive rect om sa tio co ne cti wi th th firm
stm nk ctivi tie ali st co ns ati wh ich sa la bo nu ba se nu ro us fa cto rs clud
sto ck pr ice rfo ce qu al iti nal ysi nv sto cl ie fee db ck th al ro fita il iti th fi rm wh ch mp cte
th firm us ss cti viti cl ud ng th th tituti na equ iti tr nv es tme nk se rvi ce
stm en ba kin se vic es de fi ne le cl de th thi gs ac tin un wri ter
 elli gr secu ri tie rw riti al yst sp si le th rt ae tu sk fa em er th lyst
 us eh ld sh th co sto ck th com pa gu la tio te le th ro ib se rc yst
fro tra se curi tie co co es du sp ec ifi tim per io fter th pu li ca tio es rch ep rt
 rr ton se rch cia te fu -se vic fi na ci al se vic es firm th ffe rs wid va ie ty se vic es nd pr du ts lie ts
sto rs sh ld ass tha rr ton ea ch eek ill se stm kin th us ss la ti sh ith th
co es ts se rc co er rin se rc ha ce iv ed nve tme ki g- ate co ensa tio fro thi
co ith th pa st nth xp ct wi th th xt th mo th
barrington research associ inc finra-regist broker/deal clear wedbush secur fulli
disclos basi conveni client offer sever way client facilit payment
trade barrington research order may place trade desk
trader michael hutchison head trader christoph pari email address
instant messeng address brrrmh
trade broker trade may also stepped-in barrington research trade execut broker
commiss share arrang barrington commiss share agreement numer broker wall
street complet list commiss share program barrington research particip pleas contact
salesperson trade desk
follow list provid barrington research trade alloc settlement id wedbush dtc code
question trade set account relat inform pleas call trade depart
inform contain herein obtain sourc believ reliabl guarante accuraci complet
opinion estim reflect best judgment report date subject chang without notic report intend inform
purpos constitut offer solicit buy sell secur barrington research associ inc affili offic
analyst employe may time time posit secur refer herein barrington research associ inc may act
princip agent buyer seller purchas sale secur mention report barrington research associ
inc may provid may seek provid invest bank servic compani mention report report may
reproduc form without prior written consent barrington research associ inc right reserv member finra/sipc
